De-Risked Phase 3 Strategy and FDA Alignment Underpin Buy Rating on Trevi for Haduvio in IPF Cough

In a report released today, Serge Belanger from Needham maintained a Buy rating on Trevi Therapeutics, with a price target of $22.00.

Serge Belanger has given his Buy rating due to a combination of factors tied to Trevi’s late‑stage development path for Haduvio in idiopathic pulmonary fibrosis (IPF) cough. The company has secured FDA alignment on a clear registrational strategy that includes required phase 1 work and two phase 3, randomized, double‑blind, placebo‑controlled trials designed to support a future NDA submission.

Serge Belanger’s rating is based on the view that running both phase 3 studies in parallel, with well‑defined dosing regimens and an objective, validated cough‑frequency endpoint, provides a de‑risked and timely route to potential approval. He also appears to view the recent share weakness, driven by investor disappointment that only one pivotal trial was not deemed sufficient by FDA, as creating an attractive entry point rather than signaling a fundamental change to Haduvio’s prospects.

According to TipRanks, Belanger is a 5-star analyst with an average return of 10.4% and a 47.40% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Cormedix, and Ocular Therapeutix.